Company Description
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program.
The company’s lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase 2b clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase 1b clinical trial to treat patients with metabolic dysfunction-associated steatohepatitis.
In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; PERSERIS an injectable suspension for the treatment of schizophrenia in adults; and Methydur to treat attention deficit hyperactivity disorder.
The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited.
DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
| Country | United States |
| Founded | 1998 |
| IPO Date | Sep 28, 2000 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 21 |
| CEO | James Brown |
Contact Details
Address: 10240 Bubb Road Cupertino, California 95014-4166 United States | |
| Phone | 408 777 1417 |
| Website | durect.com |
Stock Details
| Ticker Symbol | DRRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001082038 |
| CUSIP Number | 266605104 |
| ISIN Number | US2666055007 |
| Employer ID | 94-3297098 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James E. Brown D.V.M. | Co-Founder, Chief Executive Officer, President and Director |
| Timothy M. Papp M.B.A. | Chief Financial Officer and Secretary |
| Dr. Norman L. Sussman M.D. | Chief Medical Officer |
| Judy R. Joice | Senior Vice President of Operations and Corporate Quality Assurance |
| Dr. WeiQi Lin M.D., Ph.D. | Executive Vice President of Research and Development and Principal Scientist |
| Jian Li M.B.A. | Senior Vice President of Finance, Corporate Controller and Secretary |
| Dr. Su Il Yum Ph.D. | Executive Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 26, 2025 | 8-K | Current Report |
| Feb 21, 2025 | SCHEDULE 13G/A | Filing |
| Feb 21, 2025 | 8-K | Current Report |
| Jan 28, 2025 | 8-K | Current Report |
| Jan 10, 2025 | 8-K | Current Report |
| Jan 8, 2025 | SCHEDULE 13G/A | Filing |
| Nov 29, 2024 | 8-K/A | [Amend] Current report |
| Nov 25, 2024 | 8-K | Current Report |
| Nov 19, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |